Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2017
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2017
Summary
GlobalDatas clinical trial report, Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2017" provides an overview of Clostridium difficile Infections (Clostridium difficile Associated Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Clostridium difficile Infections (Clostridium difficile Associated Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Summary
GlobalDatas clinical trial report, Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2017" provides an overview of Clostridium difficile Infections (Clostridium difficile Associated Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Clostridium difficile Infections (Clostridium difficile Associated Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
TABLE OF CONTENTS
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 21
Clinical Trials by E7 Countries: Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials 23
Clinical Trials by Phase in E7 Countries 25
Clinical Trials in E7 Countries by Trial Status 26
Clinical Trials by Phase 27
In Progress Trials by Phase 28
Clinical Trials by Trial Status 29
Clinical Trials by End Point Status 31
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Clostridium difficile Infections (Clostridium difficile Associated Disease) 40
Jul 03, 2017: Pre-Clinical Results of IMM-529 in C. difficile Infection Published in Scientific Reports 40
Jun 27, 2017: Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile Infection 40
Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress 41
Jun 12, 2017: Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection 41
Jun 08, 2017: Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD 41
Jun 07, 2017: Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients Clinical Success Correlates with Improved Microbiome Diversity 42
Jun 06, 2017: Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference 42
Jun 05, 2017: Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017 42
Jun 01, 2017: Rebiotixs Phase 3-Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017 43
May 04, 2017: Rebiotixs Phase 3 ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017 43
May 02, 2017: Summit Therapeutics: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases 44
Apr 28, 2017: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summits Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection 45
Apr 11, 2017: Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile 45
Clinical Trial Profile Snapshots 47
Appendix 181
Abbreviations 181
Definitions 181
Research Methodology 182
Secondary Research 182
About GlobalData 183
Contact Us 183
Source 183
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Region, 2017* 8
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 20
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 22
Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 24
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 25
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Phase, 2017* 27
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 28
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 33
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 39
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 23
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 25
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 27
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 28
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 33
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38
GlobalData Methodology 182
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 21
Clinical Trials by E7 Countries: Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials 23
Clinical Trials by Phase in E7 Countries 25
Clinical Trials in E7 Countries by Trial Status 26
Clinical Trials by Phase 27
In Progress Trials by Phase 28
Clinical Trials by Trial Status 29
Clinical Trials by End Point Status 31
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Clostridium difficile Infections (Clostridium difficile Associated Disease) 40
Jul 03, 2017: Pre-Clinical Results of IMM-529 in C. difficile Infection Published in Scientific Reports 40
Jun 27, 2017: Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile Infection 40
Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress 41
Jun 12, 2017: Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection 41
Jun 08, 2017: Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD 41
Jun 07, 2017: Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients Clinical Success Correlates with Improved Microbiome Diversity 42
Jun 06, 2017: Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference 42
Jun 05, 2017: Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017 42
Jun 01, 2017: Rebiotixs Phase 3-Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017 43
May 04, 2017: Rebiotixs Phase 3 ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017 43
May 02, 2017: Summit Therapeutics: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases 44
Apr 28, 2017: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summits Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection 45
Apr 11, 2017: Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile 45
Clinical Trial Profile Snapshots 47
Appendix 181
Abbreviations 181
Definitions 181
Research Methodology 182
Secondary Research 182
About GlobalData 183
Contact Us 183
Source 183
List Of Tables
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Region, 2017* 8
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 20
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 22
Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 24
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 25
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Phase, 2017* 27
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 28
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 33
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 39
List Of Figures
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
Proportion of Clostridium difficile Infections (Clostridium difficile Associated Disease) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 23
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 25
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 27
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 28
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 33
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
Clostridium difficile Infections (Clostridium difficile Associated Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38
GlobalData Methodology 182
RELATED REPORTS
Clostridium difficile Toxin B (toxB or EC 3.4.22.) - Drugs in Development, 2021
Clostridium difficile Toxin B (toxB or EC 3.4.22.) - Drugs in Development, 2021Clostridium difficile Toxin B (toxB or EC 3.4.22.) - Drugs in Development, 2021 provides in depth analysis on
View ReportClostridium difficile Toxin A (toxA or EC 3.4.22.) - Drugs in Development, 2021
Clostridium difficile Toxin A (toxA or EC 3.4.22.) - Drugs in Development, 2021Clostridium difficile Toxin A (toxA or EC 3.4.22.) - Drugs in Development, 2021 provides in depth analysis on
View ReportClostridium difficile Toxin B (toxB or EC 3.4.22.) - Drugs in Development, 2021
Clostridium difficile Toxin B (toxB or EC 3.4.22.) - Drugs in Development, 2021Clostridium difficile Toxin B (toxB or EC 3.4.22.) - Drugs in Development, 2021 provides in depth analysis on
View ReportClostridium difficile Toxin A (toxA or EC 3.4.22.) - Drugs in Development, 2021
Clostridium difficile Toxin A (toxA or EC 3.4.22.) - Drugs in Development, 2021Clostridium difficile Toxin A (toxA or EC 3.4.22.) - Drugs in Development, 2021 provides in depth analysis on
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
